TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.

TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).

TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.

TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.

TS-044619 — Organophosphorus (OP) poisons including sarin, VX, and novichoks are lethal agents of chemical warfare. Their toxicity is due to their direct inhibition of acetylcholinesterase (AChE), an enzyme that is vital to the nervous system via regulation of the neurotransmitter acetylcholine (ACh). AChE in…

TS-041469 — A new compound to eliminate Salmonella biofilms to reduce typhoid fever.

TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.

TS-038027 — Novel dihdroorotate dehydrogenase (DHODH) small-molecule inhibitors for the treatment of Acute Myeloid Leukemia, Multiple Myeloma, & Graft vs. Host Disease / Leukemia.

TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.

TS-037788 — Rinses with sustained contact time and field coverage have been developed to prevent oral cancer.

TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.

TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.

TS-014819 — A new class of drugs for the treatment of Leishmania.

TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.

TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.

TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.